Poly(ADP-ribose) polymerase-1 mediates angiotensin II-induced expression of plasminogen activator inhibitor-1 and fibronectin in rat mesangial cells

Kidney and Blood Pressure Research

Volumn 34, Issue 5, 2011, Pages 320-327

  Zhu, Hengmei ^a   Jiang, Zongpei ^a   Lei, Ping ^a   Huang, Wen ^a   Yu, Xueqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiotensin II; Fibronectin; Plasminogen activator inhibitor 1; Poly(ADP ribose) polymerase 1; Rat mesangial cells

Indexed keywords

ANGIOTENSIN II; FIBRONECTIN; MESSENGER RNA; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; FIBRONECTINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS; MESANGIAL CELLS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLY(ADP-RIBOSE) POLYMERASES; RATS; RNA, SMALL INTERFERING;

EID: 80955173519     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000327344     Document Type: Article

References (44)

1. Wang H, Zhang L, Lv J: Prevention of the progression of chronic kidney disease: Practice in China. Kidney Int Suppl 2005; 94:S63-S67.
2. Xie Y, Chen X: Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am J Nephrol 2008; 28: 1-7. (Pubitemid 350126487)
3. Chen W, Wang H, Dong X, Liu Q, Mao H, Tan J, Lin J, Zhou F, Luo N, He H, Johnson RJ, Zhou SF, Yu X: Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transplant 2009; 24: 1205-1212.
4. Ikizler TA: Epidemiology of vascular disease in renal failure. Blood Purif 2002; 20: 6-10. (Pubitemid 34102502)
5. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
6. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa JM, Calise D, Pecher C, Bader M, Girolami JP, Bascands JL: In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110: 371-379. (Pubitemid 34847969)
7. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210. (Pubitemid 351160157)
8. Douillette A, Bibeau-Poirier A, Gravel SP, Clement JF, Chenard V, Moreau P, Servant MJ: The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the I-B kinase complex. J Biol Chem 2006; 281: 13275-13284. (Pubitemid 43855239)
9. Bascands JL, Schanstra JP: Obstructive nephropathy: Insights from genetically engineered animals. Kidney Int 2005; 68: 925-937. (Pubitemid 43246409)
10. Ma LJ, Fogo AB: PAI-1 and kidney fibrosis. Front Biosci 2009; 14: 2028-2041.
11. Fogo AB: Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 1999; 7: 147-159. (Pubitemid 29210177)
12. Kurogi Y: Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 2003; 23: 15-31. (Pubitemid 36024906)
13. Hassa PO, Haenni SS, Elser M, Hottiger MO: Nuclear ADP-ribosylation reactions in mammalian cells: Where are we today and where are we going? Microbiol Mol Biol Rev 2006; 70: 789-829. (Pubitemid 44484693)
14. Dawson VL, Dawson TM: Deadly conversations: Nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 2004; 36: 287-294. (Pubitemid 39619828)
15. Andrabi SA, Dawson TM, Dawson VL: Mitochondrial and nuclear cross-talk in cell death: Parthanatos. Ann N Y Acad Sci 2008; 1147: 233-241.
16. Virag L, Szabo C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375-429.
17. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M: Inhibition of GAPDH activity by poly(ADPribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003: 112: 1049-1057. (Pubitemid 38056320)
18. Szabo C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R, Chen M, Mabley JG, Kollai M: Angiotensin II-mediated endothelial dysfunction: Role of poly(ADP-ribose) polymerase activation. Mol Med 2004; 10: 28-35. (Pubitemid 39440318)
19. Szabo C, Biser A, Benko R, Bottinger E, Susztak K: Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes 2006; 55: 3004-3012. (Pubitemid 44923636)
20. Shevalye H, Maksimchyk Y, Watcho P, Obrosova IG: Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease. Biochim Biophys Acta 2010; 1802: 1020-1027.
21. Vaschetto R, Kuiper JW, Chiang SR, Haitsma JJ, Juco JW, Uhlig S, Plotz FB, Della Corte F, Zhang H, Slutsky AS: Inhibition of poly(adenosine diphosphate-ribose) polymerase attenuates ventilator-induced lung injury. Anesthesiology. 2008; 108: 261-268. (Pubitemid 351156736)
22. Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, Lee HB: Role of reactive oxygen species in TGF-α 1 -induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005; 16: 667-675. (Pubitemid 41725103)
23. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
24. Mooney A, Jackson K, Bacon R, Streuli C, Edwards G, Bassuk J, Savill J: Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via 1 - integrin-mediated survival signals. Am J Pathol 1999; 155: 599-606. (Pubitemid 29370409)
25. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34. (Pubitemid 30127593)
26. Miner JH: Renal basement membrane components. Kidney Int 1999; 56: 2016-2024. (Pubitemid 30004730)
27. Graziani G, Szabo C: Clinical perspectives of PARP inhibitors. Pharmacol Res 2005; 52: 109-118. (Pubitemid 40725605)
28. Xu B, Chiu J, Feng B, Chen S, Chakrabarti S: PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes. Diabetes Metab Res Rev 2008: 24: 404-412.
29. Chiu J, Farhangkhoee H, Xu BY, Chen S, George B, Chakrabarti S: PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 2008; 45: 385-393.
30. Nicolescu AC, Holt A, Kandasamy AD, Pacher P, Schulz R: Inhibition of matrix metalloproteinase- 2 by PARP inhibitors. Biochem Biophys Res Commun 2009; 387: 646-650.
31. Li M, Threadgill MD, Wang Y, Cai L, Lin X: Poly(ADP-ribose) polymerase inhibition down-regulates expression of metastasis-related genes in CT26 colon carcinoma cells. Pathobiology 2009; 76: 108-116.
32. Huang D, Wang Y, Yang C, Liao Y, Huang K: Angiotensin II promotes poly(ADP-ribosyl) ation of c-Jun/c-Fos in cardiac fibroblasts. J Mol Cell Cardiol 2009; 46: 25-32.
33. Casey PJ, Black JH, Szabo C, Frosch M, Albadawi H, Chen M, Cambria RP, Watkins MT: Poly(adenosine diphosphate ribose) polymerase inhibition modulates spinal cord dysfunction after thoracoabdominal aortic ischemia-reperfusion. J Vasc Surg 2005; 41: 99-107. (Pubitemid 40193347)
34. Fiorillo C, Ponziani V, Giannini L, Cecchi C, Celli A, Nassi N, Lanzilao L, Caporale R, Nassi P: Protective effects of the PARP-1 inhibitor PJ34 in hypoxic-reoxygenated cardiomyoblasts. Cell Mol Life Sci 2006; 63: 3061-3071. (Pubitemid 46072308)
35. Besson VC, Zsengeller Z, Plotkine M, Szabo C, Marchand-Verrecchia C: Beneficial effects of PJ34 and INO-1001, two novel watersoluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat. Brain Res 2005; 1041: 149-156.
36. Goebel DJ, Winkler BS: Blockade of PARP activity attenuates poly(ADP-ribosyl)ation but offers only partial neuroprotection against NMDA-induced cell death in the rat retina. J Neurochem 2006; 98: 1732-1745. (Pubitemid 44298241)
37. Pillai JB, Gupta M, Rajamohan SB, Lang R, Raman J, Gupta MP: Poly(ADP-ribose) polymerase- 1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2006; 291:H1545-H1553. (Pubitemid 44497657)
38. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000; 58: 1841-1850.
39. Lelongt B, Ronco P: Role of matrix metalloproteinases in kidney development and glomerulopathy: Lessons from transgenic mice. Nephrol Dial Transplant 2002; 17(suppl 9): 28-31.
40. Marti HP: The role of matrix metalloproteinases in the activation of mesangial cells. Transpl Immunol 2002; 9: 97-100.
41. Ha H, Lee HB: Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 2003; 14:S246-S249. (Pubitemid 36903934)
42. Knudsen BS, Harpel PC, Nachman RL: Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 1987; 80: 1082-1089. (Pubitemid 18075646)
43. Kishida M, Urakaze M, Takata M, Nobata Y, Yamamoto N, Temaru R, Sato A, Yamazaki K, Nakamura N, Kobayashi M: PGE1 inhibits the expression of PAI-1 mRNA induced by TNF-α in human mesangial cells. Exp Clin Endocrinol Diabetes 2005; 113: 365-371. (Pubitemid 41059230)
44. Yang C, Glass WF 2nd: Expression of -actinin- 1 in human glomerular mesangial cells in vivo and in vitro. Exp Biol Med (Maywood) 2008; 233: 689-693.